ALNY
ALNYLAM PHARMACEUTICALS, INC. · Healthcare · Market cap $30.1B
Insiders sold $399K net in the last 90 days ·1 seller, 0 buyers· latest Form 4 filed Oct 6, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$44.0M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Oct 6, 2026
SUPRAN BRYAN
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 43 SEC Form 4 filings (321 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Oct 6, 2026.
Inside the rolling window, 8 insiders at ALNYLAM PHARMACEUTICALS, INC. reported no open-market purchases and 34 open-market sales totaling $44.0M. The most active filer is CSO & EVP, Head of Research Fitzgerald Kevin Joseph with 9 filings. Insiders have net sold $1.5M over the trailing 6 months. The most recent open-market filing is a sale of 1,758 shares by EVP, CLO and Secretary SUPRAN BRYAN, dated Oct 2, 2026, worth $399K.
- Industry:Biotechnology
- CEO:Yvonne L. Greenstreet
- Employees:2,500
- HQ:Cambridge, MA, US
- IPO:2004-06-01
| Source | |||||||
|---|---|---|---|---|---|---|---|
SUPRAN BRYANFirst filing | EVP, CLO and Secretary | Sale | 1,758 | $399K | Oct 6 | +0.5% | SEC ↗ |
PYOTT DAVID E IFirst filing | Director | Sale | 3,830 | $1.1M | Jun 3 | -23.1% | SEC ↗ |
McLaughlin MelissaFirst filing | Chief Human Resources Officer | Sale | 1,624 | $519K | Apr 7 | -29.6% | SEC ↗ |
McLaughlin MelissaFirst filing | Chief Human Resources Officer | Sale | 2,286 | $755K | Apr 7 | — | SEC ↗ |
| CSO & EVP, Head of Research | Sale | 633 | $205K | Mar 6 | — | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 658 | $213K | Mar 6 | — | SEC ↗ | |
| EVP Chief R&D | Sale | 2,309 | $746K | Mar 6 | — | SEC ↗ | |
| EVP Chief R&D | Sale | 2,404 | $779K | Mar 6 | — | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 2,309 | $746K | Mar 6 | — | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 2,468 | $797K | Mar 6 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 2,933 | $948K | Mar 6 | — | SEC ↗ | |
| EVP Chief R&D | Sale | 1,717 | $563K | Mar 4 | — | SEC ↗ | |
| EVP Chief R&D | Sale | 1,775 | $568K | Mar 4 | — | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 1,598 | $524K | Mar 4 | — | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 1,652 | $528K | Mar 4 | — | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 2,206 | $723K | Mar 4 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 6,799 | $2.2M | Mar 4 | — | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,598 | $524K | Mar 4 | — | SEC ↗ | |
| EVP Chief R&D | Sale | 4,627 | $1.5M | Mar 2 | — | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 1,959 | $607K | Feb 17 | — | SEC ↗ | |
| CSO & EVP, Head of Research | Sale | 2,041 | $678K | Feb 17 | — | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 2,242 | $695K | Feb 17 | — | SEC ↗ | |
| EVP, Chief Commercial Officer | Sale | 1,959 | $607K | Feb 17 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 6,958 | $2.2M | Feb 17 | — | SEC ↗ | |
| EVP Chief R&D | Sale | 2,242 | $695K | Feb 17 | — | SEC ↗ |
Congress trading ALNY 15 all-time
- DSen. Cory BookerSale$1,001 - $15,0002026-08-11
- DSen. Cory BookerOther$1,001 - $15,0002026-08-11
- RRep. Jefferson ShreveSale$15,001 - $50,0002025-05-12
- DRep. Josh S. GottheimerPurchase$1,001 - $15,0002024-01-11
- DRep. Josh S. GottheimerOther$1,001 - $15,0002024-01-29
- DRep. Josh S. GottheimerSale$1,001 - $15,0002023-12-11
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does ALNY have?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has 43 SEC Form 4 filings (321 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Oct 6, 2026.
When was the most recent SEC Form 4 filing for ALNY?
The most recent Form 4 filing for ALNY on Tracefour is dated Oct 6, 2026.
Who is the most active insider at ALNY?
The most active SEC Form 4 filer at ALNY in the rolling window is CSO & EVP, Head of Research Fitzgerald Kevin Joseph, with 9 filings.
What is the net insider flow at ALNY over the last 6 months?
Over the trailing 180 days, insiders at ALNY have net sold $1.5M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ALNY in the current window?
Inside the rolling window, insiders at ALNY bought $0 and sold $44.0M based on SEC Form 4 filings.
Can I get alerts for ALNY insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at ALNYLAM PHARMACEUTICALS, INC. (ALNY). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
ALNYLAM PHARMACEUTICALS, INC. is in the Healthcare sector.